There are currently 434 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Breast Cancer participants are California, Ohio, Illinois and Michigan.
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
NCT05826964
Recruiting
The majority of patients (pts) with breast cancer have hormone receptor positive (HR+) disease, and this holds true for pts with advanced breast cancer (ABC). Currently frontline therapy for pts with HR+ ABC is antihormonal therapy with an aromatase inhibitor or selective estrogen receptor degrader plus a CDK4/6i. The proposed trial is a randomized study to further evaluate the potential benefit of switching a frontline regimen at the time that a molecular signal, ctDNA, suggests progression pri... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: University of Miami, Miami, Florida
Conditions: Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Register for Updates
Focused Ultrasound and Gemcitabine in Breast Cancer
NCT04796220
Recruiting
This study will test the use of focused ultrasound ablation, low-dose gemcitabine (a chemotherapy) and the combination of focused ultrasound ablation plus low-dose gemcitabine in patients with early-stage breast cancers. We will be testing the effects of each of these regimens on cells in the immune system. We hypothesize that the combination of focused ultrasound ablation and gemcitabine will decrease myeloid-derived suppressor cells and will increase T cell activity. We also hypothesize that f... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Breast Cancer, Breast Neoplasms
Register for Updates
MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial
NCT06954337
Recruiting
Many people with cancer spend a lot of time and money traveling to and from the doctor's office for cancer care. MSK's goal is to make getting cancer care easier by cutting down the need to make in-person visits to MSK. MSK is trying to do this through a new option called enhanced telehealth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Breast Cancer, Prostate Cancer
Register for Updates
Lymphedema Surveillance Study
NCT02743858
Recruiting
This study is being done to find out how many women develop lymphedema after an axillary lymph node dissection. The investigators also want to look for reasons why some women get lymphedema and others don't. Specifically, the investigators want to do tests on the breast tissue that is removed at the time of surgery to see if they can identify inflammation in the breast tissue, which may increase a woman's risk for lymphedema. The investigators will also ask the patient to answer questions to see... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Memorial Sloan Kettering Basking Ridge (Consent only), Basking Ridge, New Jersey +6 locations
Conditions: Breast Cancer, Lymphedema
Register for Updates
Magnetic Resonance Imaging of Breast Cancer
NCT01035112
Recruiting
To compare magnetic resonance imaging (MRI) with more well established diagnostic imaging techniques to determine which method best finds and defines breast cancer.
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
06/27/2025
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Breast Cancer, Breast Cancer Non-invasive Breast Cancer
Register for Updates
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT02830724
Recruiting
Background: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. This is called gene transfer. For this study, researchers will modify the person s white blood cells with anti-CD70. Objectives: To see if a gene transfer with anti-CD70 cells can safely shrink tumors and to be certain the treatment is safe. Eligibility: Adults age 18... Read More
Gender:
ALL
Ages:
Between 18 years and 72 years
Trial Updated:
06/27/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Pancreatic Cancer, Renal Cell Cancer, Breast Cancer, Melanoma, Ovarian Cancer
Register for Updates
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)
NCT05573555
Recruiting
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer. This study is seeking participants who have breast cancer that: * is advanced, may have spread to other organs (metastatic) and cannot be fully treated by surgery or radiation therapy * is sensitive to hormonal therapy (it is called estrogen receptor positive); and * is no... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Stanford Women's Cancer Center, Palo Alto, California +44 locations
Conditions: Breast Cancer
Register for Updates
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
NCT06239467
Recruiting
OKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of OKI-219 as monotherapy and in combination with fulvestrant or trastuzumab. Phase 1a (Part A) will investigate escalating doses of OKI-219 monotherapy, and Phase 1b will investigate OKI-219 (at a tolerated dose determined in Part A) in combination with standard dose fulvestrant (Part B) or standard dose trastuzum... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: California Cancer Associates for Research and Excellence, Encinitas, California +33 locations
Conditions: Advanced Cancer, Breast Cancer
Register for Updates
Study Assessing QBS72S For Treating Brain Metastases
NCT05305365
Recruiting
This study is to evaluate the efficacy and safety of QBS72S in participants with advanced, relapsed, metastatic cancer with CNS involvement
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Stanford Cancer Institute, Palo Alto, California
Conditions: Brain Metastases, Breast Cancer, Lung Cancer, Leptomeningeal Disease, LMD
Register for Updates
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
NCT05283330
Recruiting
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Northwestern University Robert H Lurie Medical Research, Chicago, Illinois +3 locations
Conditions: Cervical Cancer, Prostate Cancer Metastatic, Breast Cancer, Colon Cancer, NSCLC, Cutaneous Melanoma
Register for Updates
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470
Recruiting
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study. Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: The Angeles Clinic and Research Institute, Los Angeles, California +10 locations
Conditions: Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC)
Register for Updates
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +216 locations
Conditions: Breast Cancer
Register for Updates